Save the Date for the National Lipid Association 2020 Spring Clinical Lipid Update, February 28 – March 1, 2020 at the Grand Hyatt Denver. The meeting will feature innovative topics in lipidology, the role of genetic testing in ASCVD Risk Assessment, the latest in pharmacotherapy for obesity and highlight the latest NLA position statement hot topics.
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management.
Type of Activity
At the conclusion of this activity, all participants should be able to:
- Discuss strategies to improve the knowledge, skills or performance of the healthcare team;
Session I- Drugs in the Pipeline
- Discuss the role of novel therapies for the future clinical management of patients with dyslipidemia.
Session II: Fortune-Tellers and Crystal Balls in ASCVD: Divining and Refining Risk Assessment
- Explain new refinements in the assessment of ASCVD risk in primary prevention patients.
- Recognize challenges in classifying patient risk for ASCVD.
- Summarize recent advancements in the use of genetics in primary prevention ASCVD risk assessment.
Session III: One Size Does Not Fit All: Evidence-Based use of Statin Therapy in Special Populations
- Discuss potential statin drug-drug interactions in special populations.
- Describe the appropriate usage of statins in patients with chronic kidney disease.
- Identify potential benefits and risks of statin use in the elderly.
Session IV: Improving Patient Outcomes in Statin Resistance and Intolerance
- Summarize the evidence-based recommendations for current and emerging non-statin therapeutic interventions.
- Demonstrate the potential use of non-statin therapies in an overall cardiovascular disease risk reduction management plan in patients not able to tolerate or resistant to statin therapy.
Session V: Weight Loss Strategies
- Outline the impact of various diets on short-term and long-term weight loss.
- Discuss pharmacologic therapy options for the treatment of obesity.
Session VI: The Journal of Clinical Lipidology Live Roundtable
- Review the practical application of recent publications to the clinical evaluation and management of patients with dyslipidemia.
Session VII: Lifestyle and Diet Challenges
- Compare and Contrast nutrition options in the management of patients with dyslipidemia.
- Demonstrate counseling techniques for modifying diet and lifestyle.
- Outline the impact of various diets on short-term and long-term cardiovascular risks.
Session VIII: Is the Rising Tide of Support for EPA Warranted or Just Another Fish-Tale?
- Describe the evidence to support the benefit of omega-3 fatty acids.
- Identify the recent clinical trial evidence for the use of omega 3 fatty acids in dyslipidemia management.
- Discuss evidence that supports the benefits of nutritional supplements and dietary counseling in reducing cardiovascular disease.
|Friday, February 28|
|3:45 - 3:55 PM||Chapter Presidents Welcome & Introduction|
|Session I- Drugs in the Pipeline- Moderator: Joseph J. Saseen, PharmD, CLS, FNLA|
|4:00 - 4:05 PM||Pre-Session Assessment|
|4:05 - 4:20 PM||Pemafibrate||Savitha Subramanian, MD|
|4:20 - 4:35 PM||Bempedoic Acid||Anne C. Goldberg, MD, FNLA|
|4:35 - 4:50 PM||Inclisiran||Christie M. Ballantyne, MD, FNLA|
|4:50 - 5:05 PM||Update on Evinacumab: ANGPTL3 and Lipid Management||P. Barton Duell, MD, FNLA|
|5:05 - 5:35 PM||Speakers Panel with Moderator|
|5:35 - 6:00 PM||Q&A Panel & Post-Session Assessment|
|6:00 - 7:00 PM||Welcome Reception in Exhibit Hall|
|7:00 - 9:00 PM||CME/ CE Symposium|
|Saturday, February 29|
|6:30 - 7:50 AM||CME/ CE Symposium|
|7:00 - 7:50 AM||Breakfast in Exhibit Hall|
|7:50 - 8:00 AM||Opening Remarks|
|Session II: Fortune-Tellers and Crystal Balls in ASCVD: Divining and Refining Risk Assessment|
|8:00 - 8:05 AM||Pre-Session Assessment|
|8:05 - 8:25 AM||Primary Prevention: Seeking Individuality and Personalization of Preventive Therapies||Margo B. Minissian, PhD, ACNP, CLS, FNLA|
|8:25 - 8:45 AM||Secondary Prevention: Not All ASCVD is Created Equal||Kim K. Birtcher, PharmD, CLS, FNLA|
|8:45 - 9:05 AM||Beyond the Usual Suspects: What is the Current Role of Genetic Testing in ASCVD Risk Assessment?||Zahid Ahmad, MD|
|9:05 - 9:30 AM||Q&A Panel & Post-Session Assessment|
|9:30 - 10:00 AM||Break in Exhibit Hall|
|Session III: One Size Does Not Fit All: Evidence-Based use of Statin Therapy in Special Populations|
|10:00 - 10:05 AM||Pre-Session Assessment|
|10:05 - 10:25 AM||Complex Drug-Drug Interactions||Donald G. Lamprecht, Jr., PharmD, BCPS, CLS, FNLA|
|10:25 - 10:45 AM||SHARPening Statin Therapy Recommendations in Chronic Kidney Disease||Rachel Lowe, PharmD, BCPS|
|10:45 - 11:05 AM||Statin therapy in Older Primary Prevention Patients||Eric K. Gupta, PharmD, CLS, FNLA|
|11:05 - 11:25 AM||Case Presentation and Panel Discussion|
|11:25 - 11:45 AM||Q&A Panel & Post-Session Assessment|
|11:45 AM - 12:00 PM||PLA & SWLA Chapter News & Notes|
|12:00 - 1:00 PM||Lunch in Exhibit Hall|
|12:00 - 1:00 PM||Expert Theaters|
|Session IV: Improving Patient Outcomes in Statin Resistance and Intolerance|
|1:00 - 1:05 PM||Introductions & Pre-Session Assessment|
|1:05 - 1:10 PM||Statin Intolerant Patient Case Overview||Peter H. Jones, MD, FNLA|
|1:10 - 1:25 PM||Expert Case Management: Strategies to Improve Adherence||Mary Katherine Cheeley, PharmD, CLS, FNLA|
|1:25 - 1:45 PM||Expert Case Management: Alternative or Additive Therapeutic Approaches||Kevin C. Maki, PhD, CLS, FNLA|
|1:45 - 2:10 PM||Expert Case Management: What’s next after a myocardial infarction (MI)?||Alan S. Brown, MD, FNLA|
|2:10 - 2:25 PM||Panel Discussion Q&A|
|2:25 - 2:30 PM||Post-Session Assessment|
|2:30 - 2:40 PM||Break|
|Session V: Weight Loss Strategies: Focus on Fasting and Pharmacotherapy Strategies|
|2:40 - 2:45 PM||Pre-Session Assessment|
|2:45 - 3:05 PM||Intermittent Fasting with Focus on Cardiometabolic Risk Factors||Tracy Severson, RDN, LD|
|3:05 - 3:25 PM||Update on Pharmacotherapy for Obesity||Harold E. Bays, MD, FNLA|
|3:25 - 3:40 PM||Q&A Panel & Post-Session Assessment|
|3:40 - 3:50 PM||Break|
|Session VI: The Journal of Clinical Lipidology Live Roundtable|
|3:50 - 3:55 PM||Overview from Moderator|
|3:55 - 4:05 PM||What you may have Missed from the Journal of Clinical Lipidology in 2019: High-Level Review of Findings from Three Important Articles||Catherine Derington, PharmD, MS|
|4:05 - 4:15 PM||Joseph C. DeBoe, DNP, ACNPC-AG, CCRN|
|4:15 - 4:25 PM||Lauren A. Williams, RD, MCN, LD|
|4:25 - 5:00 PM||Experts Panel Roundtable with John R. Guyton, MD, FNLA and Faculty P. Barton Duell, MD, FNLA and Nathan D. Wong, PhD, FNLA|
|5:00 - 5:20 PM||Q&A Panel|
|5:30 - 7:30 PM||CME/ CE Symposium|
|Sunday, March 1|
|7:00 - 7:50 AM||Breakfast|
|7:50 - 8:00 AM||Opening Remarks|
|Session VII: Lifestyle and Diet Challenges|
|8:00 - 8:05 AM||Pre-Session Assessment|
|8:05 - 8:25 AM||Ultra-Processed vs. Unprocessed Foods||Tracy Severson, RDN, LD|
|8:25 - 8:45 AM||Behavioral Treatment Programs to Address Lifestyle and Diet Challenges in Primary Care||Jun Ma, MD, PhD|
|8:45 - 9:05 AM||Low-CHO/Very-Low-CHO Diets Scientific Statement||Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA|
|9:05 - 9:30 AM||Q&A Panel & Post-Session Assessment|
|9:30 - 9:40 AM||Break|
|Session VIII: Is the Rising Tide of Support for EPA Warranted or Just Another Fish-Tale?|
|9:40 - 9:45 AM||Pre-Session Assessment|
|9:45 - 10:05 AM||Physiologic and Epidemiologic Evidence for EPA||Kevin C. Maki, PhD, CLS, FNLA|
|10:05 - 10:25 AM||AHA Scientific Statement, Review of Clinical Trial Evidence for Omega3s||Ann C. Skulas-Ray, PhD|
|10:25 - 10:45 AM||Dietary Interventions and Nutritional Supplements: Effects on Cardiovascular Outcomes||Sarah L. Anderson, PharmD|
|10:45 - 11:05 AM||Q&A Panel & Post-Session Assessment|
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.00 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation Statement
The National Lipid Association designates this live activity for a maximum of 12.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12.00 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.
Pharmacist Accreditation Statement
Universal Activity Number JA0007192-0000-20-001-L01-P (Application)
This Activity has been approved for 12.00 contact hour(s) (1.2 CEUs) of the Accreditation Council for Pharmacy Education
The maximum number of hours awarded for this CE activity is 12.0 contact hours.
Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
Criteria for Success:
Statements of credit will be awarded based on the participant´s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme.
For Pharmacists: Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
For Dietitians: Upon completion of the activity evaluation form, dietitians may submit evaluations of the quality of activities/materials to CDR. Poor evaluations of activities/materials may trigger an audit of the activities / materials by CDR.
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity.
Full notification of commercial support will be provided in the activity syllabus.
Foundations of Lipidology Course
Thursday, February 27 • 8:00 am–5:35 pm
Friday, February 28 • 8:00 am–2:30 pm
$550 NLA Members, $950 Non-Members, $0 Trainees
The NLA's Foundations of Lipidology course provides an introductory review of the core curriculum in Clinical Lipidology. This course is designed for any healthcare professional seeking to learn the fundamentals of Lipidology. Experts in Lipidology will lecture on basic concepts and guide participants through interactive learning scenarios that provide the knowledge and tools necessary to work effectively in a lipid practice and prepare for advanced training.
This course is particularly useful to review core elements of Clinical Lipidology and is appropriate for clinicians from the full spectrum of clinical experience including Physicians, Physician Assistants, Nurse Practitioners, Pharmacist, Exercise Physiologists, and Dietitians who are in any phase of training, or even experienced physicians who are looking to take a deeper dive into Lipidology.
The Foundations of Lipidology is offered as a two-day course prior to NLA meetings (Clinical Lipid Updates [CLU] and Scientific Sessions).
Masters in Lipidology Course
Thursday, February 27 • 7:30 am–5:40 pm
Friday, February 28 • 7:30 am–2:20 pm
$750 NLA Members, $1,250 Non-Members, $395 Trainees
The NLA's Masters in Lipidology course provides an advanced examination of the core curriculum in Clinical Lipidology. This course is designed for any health care professional with experience in Lipidology who desires advanced training. Experts in the field of Lipidology will lecture on advanced concepts and guide participants through interactive learning scenarios that provide tools and skills to further advance personal standards of practice. It is recommended that attendees have already completed preparatory coursework (e.g., Foundations of Lipidology or similar core curriculum training).
This course is particularly useful to explore the details of Clinical Lipidology and is appropriate for clinicians from the full spectrum of clinical experience including Physicians, Physician Assistants, Nurse Practitioners, Pharmacists, Exercise Physiologists, and Dietitians who are in any phase of training, or even experienced physicians who are looking to take a deeper dive into Lipidology.
Masters in Lipidology is offered as a two-day course prior to NLA meetings (Clinical Lipid Updates [CLU] and Scientific Sessions).
Tailoring Lipid Lowering Therapy to Meet Individualized Goals
Friday, February 28
7:00 - 7:30pm - Registration and Dinner provided by the NLA
7:30 - 9:00pm - Program
Room: Aspen Ballroom
James A. Underberg, MS, MD
Harold E. Bays, MD
Mark Cziraky, PharmD
Pamela B. Morris, MD
"Tailoring Lipid Lowering Therapy to Meet Individualized Goals" will be an interactive, dynamic session focused on assessing current trends related to lipid lowering, enhancing the role of the care team to improve patient outcomes, and applying new guidelines to patient care. The session will conclude with patient cases where you will apply the above concepts to improve treatment and outcomes in common and challenging patient cases... are you up to the challenge?
Hosted by Medscape
This is an independent satellite CME/CE symposium held in conjunction with the NLA 2020 Clinical Lipid Update. It is not part of the official sessions as planned by the NLA Scientific Meetings Committee.
Saturday, February 29 12:00 - 1:00pm
Lunch provided by the NLA
VASCEPA®️ (icosapent ethyl): Elevating the Standard of Care
Room: Mt. Sopris B
James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA
Clinical Assistant Professor of Medicine
NYU Medical School & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
Hosted by Amarin Pharma Inc.
Severe Dyslipidemia Management & Cardiovascular Risk: The Good, the Bad & the Ugly
Room: Mt. Sopris A
Marc-Andre Cornier, M.D. (Moderator)
Professor of Medicine
Associate Division Head, Division of Endocrinology, Metabolism and Diabetes
Associate Director, CU Anschutz Health and Wellness Center
University of Colorado School of Medicine
Anschutz Medical Campus
Daniel E. Soffer, MD FNLA
University of Pennsylvania Health System
Internal Medicine/ Clinical Lipidology
Perelman Center for Advance Medicine
Chief Technology Officer
The FH Foundation
Hosted by Kaneka Pharma America
Expert Theaters are not part of the National Lipid Association Clinical Lipid Update, as planned by the NLA Education Committee, and is not being certified for CME/CE credit.
|Akcea Therapeutics Inc.Exhibit# 109
|Alexion PharmaceuticalsExhibit# 102
|Amarin Pharma Inc.Exhibit# 101
|Ambry Genetics, a Konica Minolta CompanyExhibit# 105
|Amgen Inc.Exhibit# 107
|Amryt Pharma Exhibit# 113
|FCS FoundationExhibit# 108
|Kaneka Pharma AmericaExhibit# 112
|Medicure Inc.Exhibit# 111
|National Lipid AssociationExhibit# 106
|Phosphorus DiagnosticsExhibit# 110
|Religen Inc / Vascular StrategiesExhibit# 103
|Retrophin, Inc.Exhibit# 104
Register for 2020 Spring Clinical Lipid Update
Registration: Online registration and payment must be received no later than February 28, 2020. By registering for this meeting, attendee understands and agrees that attendee’s name, city, and state may be shared with other attendees and exhibitors. By visiting the virtual exhibit hall, attendee understands, agrees and consents to the sharing of attendee’s contact information with the participating companies.
Photography: Photographs and/or video may be taken as part of the registered event. By registering for this event, you grant the National Lipid Association full rights to use the images resulting from the photography/video filming and any reproductions or adaptations of the images for promotional purposes. This may include (but is not limited to), the right to use them in print and online platforms, social media, press releases and other outlets.
Cancellation: Telephone cancellations will not be accepted. A written notice of cancellation must be received no later than November 10, 2020. There will be a $50 fee for all cancellations. There will be no refunds if cancelling within 30 days of the start of the meeting date.
Attendees who need special reasonable accommodations or who have special needs should contact the meeting organizers at 904-998-0854.